HUP0303125A2 - Bcl-2 rendellenességek kezelésére szolgáló eljárások bcl-2 antiszenz oligomerekkel - Google Patents

Bcl-2 rendellenességek kezelésére szolgáló eljárások bcl-2 antiszenz oligomerekkel

Info

Publication number
HUP0303125A2
HUP0303125A2 HU0303125A HUP0303125A HUP0303125A2 HU P0303125 A2 HUP0303125 A2 HU P0303125A2 HU 0303125 A HU0303125 A HU 0303125A HU P0303125 A HUP0303125 A HU P0303125A HU P0303125 A2 HUP0303125 A2 HU P0303125A2
Authority
HU
Hungary
Prior art keywords
bcl
treatment
antisense oligomers
antisense
disorder
Prior art date
Application number
HU0303125A
Other languages
English (en)
Hungarian (hu)
Inventor
Howard Fingert
Robert E. Klem
Raymond P. Warrel
Original Assignee
Genta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27397795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0303125(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genta Incorporated filed Critical Genta Incorporated
Publication of HUP0303125A2 publication Critical patent/HUP0303125A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0303125A 2000-08-25 2001-08-23 Bcl-2 rendellenességek kezelésére szolgáló eljárások bcl-2 antiszenz oligomerekkel HUP0303125A2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22797000P 2000-08-25 2000-08-25
US23700900P 2000-09-29 2000-09-29
US09/709,170 US7795232B1 (en) 2000-08-25 2000-11-10 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
PCT/US2001/026414 WO2002017852A2 (en) 2000-08-25 2001-08-23 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Publications (1)

Publication Number Publication Date
HUP0303125A2 true HUP0303125A2 (hu) 2003-12-29

Family

ID=27397795

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303125A HUP0303125A2 (hu) 2000-08-25 2001-08-23 Bcl-2 rendellenességek kezelésére szolgáló eljárások bcl-2 antiszenz oligomerekkel

Country Status (32)

Country Link
US (2) US7795232B1 (https=)
EP (2) EP1313514B1 (https=)
JP (1) JP2004507480A (https=)
KR (1) KR20030034153A (https=)
CN (1) CN1471408A (https=)
AP (1) AP2003002761A0 (https=)
AT (1) ATE432717T1 (https=)
AU (2) AU2001288373B2 (https=)
BG (1) BG107641A (https=)
BR (1) BR0113447A (https=)
CA (1) CA2419480A1 (https=)
CY (1) CY1109340T1 (https=)
CZ (1) CZ301582B6 (https=)
DE (1) DE60138892D1 (https=)
DK (1) DK1313514T3 (https=)
DZ (1) DZ3471A1 (https=)
EA (1) EA005424B1 (https=)
EE (1) EE200300074A (https=)
ES (1) ES2327904T3 (https=)
GE (1) GEP20063934B (https=)
HR (1) HRP20030102A2 (https=)
HU (1) HUP0303125A2 (https=)
IL (1) IL154409A0 (https=)
MX (1) MXPA03001575A (https=)
NO (1) NO20030858L (https=)
OA (1) OA12586A (https=)
PL (1) PL363050A1 (https=)
PT (1) PT1313514E (https=)
SK (1) SK3652003A3 (https=)
UA (1) UA77945C2 (https=)
WO (1) WO2002017852A2 (https=)
YU (1) YU13603A (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US7309692B1 (en) 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
CA2992643C (en) 2002-03-13 2019-06-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
EP1572970A4 (en) * 2002-11-14 2006-11-15 Genta Salus Llc OLIOGONUCLEOTIDES INHIBITORS DIRECTED ON BCL-2
AU2003295598B2 (en) 2002-11-15 2009-12-24 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
DE10258677A1 (de) * 2002-12-13 2004-06-24 Elez, Vera, Dr. Kombinations-antisense-Oligonukleotid-Krebstherapie
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2516553C (en) 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
EP1640452A4 (en) 2003-05-30 2009-12-23 Nippon Shinyaku Co Ltd OLIGOBICATENARY RNA INHIBITING BCL-2 EXPRESSION AND MEDICINAL COMPOSITION CONTAINING THE SAME
ES2609234T3 (es) 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
CA2551267C (en) 2003-12-23 2012-05-01 Genomic Health, Inc. Universal amplification of fragmented rna
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
AU2013203202B2 (en) * 2004-08-26 2017-02-16 Engeneic Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially derived intact minicells
EP2386640B1 (en) 2004-08-26 2015-01-28 EnGeneIC Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
JP5020088B2 (ja) 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
EP1815014B1 (en) 2004-11-05 2012-03-21 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
CA2631677C (en) * 2005-12-01 2014-08-12 Pronai Therapeutics, Inc. Amphoteric liposome formulation
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
CN100368424C (zh) * 2006-07-21 2008-02-13 福建金山生物制药股份有限公司 抑制肿瘤的反义核苷酸
US20080171718A1 (en) * 2006-11-08 2008-07-17 Brown Bob D Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents
DE102007020554A1 (de) * 2007-04-27 2008-10-30 Henkel Ag & Co. Kgaa Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
WO2009071681A2 (en) * 2007-12-07 2009-06-11 Santaris Pharma A/S Rna antagonist compounds for the modulation of bcl-2
JP2012509878A (ja) * 2008-11-21 2012-04-26 アイシス ファーマシューティカルズ， インコーポレーテッド ドセタキセルおよびアンチセンスオリゴヌクレオチドを含む、抗腫瘍併用療法
AU2010277554B2 (en) 2009-07-30 2015-02-19 Antisense Pharma Gmbh Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system
KR101853509B1 (ko) * 2010-01-06 2018-04-30 큐알엔에이, 인크. 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
KR20240129101A (ko) * 2015-07-07 2024-08-27 제넨테크, 인크. 항-her2 항체-약물 접합체 및 bcl-2 억제제를 사용한 병용 요법
ES2965461T3 (es) 2015-08-03 2024-04-15 Biokine Therapeutics Ltd Inhibidor de CXCR4 para el tratamiento del cáncer
CN115515686A (zh) * 2020-03-18 2022-12-23 纽约州州立大学研究基金会 修饰的短干扰rna组合物及其在癌症治疗中的用途
WO2021231486A1 (en) * 2020-05-13 2021-11-18 Unity Biotechnology, Inc. Cancer treatment by senescence induction followed by a senolytic

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5098890A (en) 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
EP0633934A1 (en) 1992-04-02 1995-01-18 Imperial Cancer Research Technology Limited Modified cells and method of treatment
JPH08506087A (ja) 1992-10-21 1996-07-02 テンプル ユニバーシティ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション ガン処置のための抗腫瘍薬とアンチセンスオリゴヌクレオチドの組み合わせ
US5550019A (en) 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US5783683A (en) * 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression

Also Published As

Publication number Publication date
GEP20063934B (en) 2006-10-10
OA12586A (en) 2006-06-07
EA200300294A1 (ru) 2003-08-28
PT1313514E (pt) 2009-09-01
US7795232B1 (en) 2010-09-14
DZ3471A1 (fr) 2002-03-07
AP2003002761A0 (en) 2003-06-30
WO2002017852A2 (en) 2002-03-07
DK1313514T3 (da) 2009-10-12
NO20030858L (no) 2003-04-24
EP2135623A1 (en) 2009-12-23
YU13603A (sh) 2006-05-25
ES2327904T3 (es) 2009-11-05
EE200300074A (et) 2004-12-15
SK3652003A3 (en) 2003-08-05
HRP20030102A2 (en) 2005-04-30
WO2002017852A3 (en) 2003-04-03
NO20030858D0 (no) 2003-02-24
PL363050A1 (en) 2004-11-15
MXPA03001575A (es) 2004-11-01
EP1313514B1 (en) 2009-06-03
ATE432717T1 (de) 2009-06-15
DE60138892D1 (de) 2009-07-16
HK1056505A1 (en) 2004-02-20
KR20030034153A (ko) 2003-05-01
AU8837301A (en) 2002-03-13
CN1471408A (zh) 2004-01-28
BR0113447A (pt) 2003-07-08
IL154409A0 (en) 2003-09-17
EA005424B1 (ru) 2005-02-24
CZ2003848A3 (cs) 2003-11-12
US20100216867A1 (en) 2010-08-26
EP1313514A4 (en) 2005-07-13
UA77945C2 (en) 2007-02-15
CY1109340T1 (el) 2014-07-02
CA2419480A1 (en) 2002-03-07
BG107641A (bg) 2004-01-30
EP1313514A2 (en) 2003-05-28
AU2001288373B2 (en) 2006-05-11
JP2004507480A (ja) 2004-03-11
CZ301582B6 (cs) 2010-04-21

Similar Documents

Publication Publication Date Title
HUP0303125A2 (hu) Bcl-2 rendellenességek kezelésére szolgáló eljárások bcl-2 antiszenz oligomerekkel
CY1118849T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
WO2003030934A3 (en) Cpg formulations and related methods
HUP0203035A2 (hu) Prosztatarák terápiájára és diagnózisára alkalmas vegyületek és eljárások
ATE234274T1 (de) Derivate des adamantan
MXPA06000619A (es) Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
IL178748A0 (en) Methods for treatment and management of lung cancers using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
MY112405A (en) Method of tumer treatment.
HUP0303927A2 (hu) Anti-angiogén ágensek és TNF-alfa alkalmazása kombinációs kezelésre
MY137435A (en) Retinoid compounds (i)
HUP0300290A2 (hu) Érkárosító hatású kombinácíós készítmény és terápia
UA32457C2 (uk) Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
TW200501945A (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
DE69633396D1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
WO2004056971A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
AP9801286A0 (en) Therapeutic compounds.
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
MXPA04001912A (es) Aminobenzofenonas novedosas.
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
MX9702671A (es) Derivados metalocenicos de diariletileno, metodos de preparacion y composiciones farmaceuticas que contienen estos derivados.
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees